piperidines and vorapaxar

piperidines has been researched along with vorapaxar* in 1 studies

Other Studies

1 other study(ies) available for piperidines and vorapaxar

Article	Year
Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11 The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients. Topics: Administration, Oral; Alkaloids; Animals; Furans; Humans; In Vitro Techniques; Lactones; Macaca fascicularis; Naphthalenes; Piperidines; Platelet Aggregation Inhibitors; Pyridines; Rats; Receptors, Thrombin; Structure-Activity Relationship	2008

Article

Year

Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity.

Journal of medicinal chemistry, 2008, Jun-12, Volume: 51, Issue:11

The discovery of an exceptionally potent series of thrombin receptor (PAR-1) antagonists based on the natural product himbacine is described. Optimization of this series has led to the discovery of 4 (SCH 530348), a potent, oral antiplatelet agent that is currently undergoing Phase-III clinical trials for acute coronary syndrome (unstable angina/non-ST segment elevation myocardial infarction) and secondary prevention of cardiovascular events in high-risk patients.

Topics: Administration, Oral; Alkaloids; Animals; Furans; Humans; In Vitro Techniques; Lactones; Macaca fascicularis; Naphthalenes; Piperidines; Platelet Aggregation Inhibitors; Pyridines; Rats; Receptors, Thrombin; Structure-Activity Relationship

2008